Exactech (NASDAQ: EXAC) and Cardiovascular Systems (NASDAQ:CSII) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
Volatility and Risk
Exactech has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Cardiovascular Systems has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Exactech and Cardiovascular Systems, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Exactech currently has a consensus price target of $49.00, suggesting a potential downside of 2.97%. Cardiovascular Systems has a consensus price target of $31.50, suggesting a potential upside of 27.22%. Given Cardiovascular Systems’ higher probable upside, analysts plainly believe Cardiovascular Systems is more favorable than Exactech.
Valuation and Earnings
This table compares Exactech and Cardiovascular Systems’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cardiovascular Systems||$204.91 million||4.12||-$1.79 million||($0.06)||-412.60|
Exactech has higher revenue and earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Exactech, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
66.3% of Exactech shares are held by institutional investors. Comparatively, 74.9% of Cardiovascular Systems shares are held by institutional investors. 28.3% of Exactech shares are held by insiders. Comparatively, 3.3% of Cardiovascular Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Exactech and Cardiovascular Systems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Exactech beats Cardiovascular Systems on 8 of the 13 factors compared between the two stocks.
Exactech, Inc. develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines. The Company distributes joint replacement systems, including knee, hip, spine and extremity implant systems, and biologic products and services and bone cement materials used in orthopedic surgery and dental procedures. The Exactech Knee System provides solutions for partial, primary and revision total knee arthroplasty. Its hip solutions address the continuum of hip arthroplasty. It manufactures and distributes various products and services designed for the healing and regeneration of bone and soft tissue, including products, which contain human allograft.
About Cardiovascular Systems
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.